Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | RAD52 | P43351 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | STAT3 | P40763 | 2/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761800 | 1.00 | P2RX3 (1.00) | P2RX3KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL4762047 | 0.81 | P2RX3 (0.69) | P2RX3KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL4762472 | 0.81 | P2RX3 (0.68) | P2RX3HPGDLMNA | |
| SCHEMBL4763232 | 0.77 | P2RX3 (0.62) | P2RX3 | |
| SCHEMBL4760984 | 0.76 | P2RX3 (0.61) | P2RX3KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL348602 | 0.72 | KDM4E (1.00) | P2RX3KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL5462933 | 0.70 | P2RX3 (0.53) | P2RX3KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL348972 | 0.69 | KDM4E (0.53) | P2RX3KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL4791982 | 0.67 | P2RX3 (0.50) | P2RX3 | |
| SCHEMBL18282642 | 0.66 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4266137-B1 | SYSTEM AND ADAPTIVE METHOD OF CANNING TUNA | HERMASA CANNING TECH S A (ES) | 2024-09-25 | — | — | EP | disclosed |
| EP-4426280-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Gurba, Alexandre (CH) | 2024-09-11 | — | — | EP | disclosed |
| US-20230339637-A1 | System and adaptive method of canning tuna | HERMASA CANNING TECHNOLOGY, S.A. (ES) | 2023-10-26 | — | — | US | disclosed |
| EP-4266137-A1 | SYSTEM AND ADAPTIVE METHOD OF CANNING TUNA | Hermasa Canning Technology S.A. (ES) | 2023-10-25 | — | — | EP | disclosed |
| CN-110770209-B | Novel 5-hydroxypyridine compounds useful as P2X1 and P2X3 receptor antagonists and pharmaceutical compositions containing the same | 光州科学技术院 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | disclosed |
| EP-4197533-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Guerin, Patrick (CH) | 2023-06-21 | — | — | EP | disclosed |
| CN-110062763-B | Peptide modulators of purinergic receptors | 未来镇痛药有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-11319289-B2 | 5-hydroxy pyridine-based compound for use as P2X1 and P2X3 receptor antagonist and pharmaceutical composition comprising same | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319289-B2 | 5-hydroxy pyridine-based compound for use as P2X1 and P2X3 receptor antagonist and pharmaceutical composition comprising same | P2RX5, P2RX3, P2RX1 | P2RX3 2/4885KDM4E 1863/4885ALDH1A1 1351/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | P2RX3 2/4885KDM4E 4410/4885ALDH1A1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.